...
首页> 外文期刊>Diagnostic pathology >Expression of ck-19, galectin-3 and hbme-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis
【24h】

Expression of ck-19, galectin-3 and hbme-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis

机译:ck-19,galectin-3和hbme-1在甲状腺病变中的表达:系统评价和诊断性荟萃分析

获取原文
           

摘要

Background To distinguish between malignant and benign lesions of the thyroid gland histological demonstration is often required since the fine-needle aspiration biopsy method applied pre-operatively has some limitations. In an attempt to improve diagnostic accuracy, markers using immunocytochemistry and immunohistochemistry techniques have been studied, mainly cytokeratin-19 (CK-19), galectin-3 (Gal-3) and Hector Battifora mesothelial-1 (HBME-1). However, current results remain controversial. The aim of the present article was to establish the diagnostic accuracy of CK-19, Gal-3 and HBME-1 markers, as well as their associations, in the differentiation of malignant and benign thyroid lesions. Methods A systematic review of published articles on MEDLINE and The Cochrane Library was performed. After establishing inclusion and exclusion criteria, 66 articles were selected. The technique of meta-analysis of diagnostic accuracy was employed and global values of sensitivity, specificity, area under the summary ROC curve, and diagnostic odds ratio (dOR) were calculated. Results For the immunohistochemistry technique, the positivity of CK-19 for the diagnosis of malignant thyroid lesions demonstrated global sensitivity of 81% and specificity of 73%; for Gal-3, sensitivity of 82% and specificity of 81%; and for HBME-1, sensitivity of 77% and specificity of 83%. The association of the three markers determined sensitivity of 85%, specificity of 97%, and diagnostic odds ratio of 95.1. Similar results were also found for the immunocytochemistry assay. Conclusion This meta-analysis demonstrated that the three immunomarkers studied are accurate in pre- and postoperative diagnosis of benign and malignant thyroid lesions. Nevertheless, the search for other molecular markers must continue in order to enhance this diagnostic accuracy since the results found still show a persistency of false-negative and false-positive tests. Virtual slides Http://www.diagnosticpathology.diagnomx.eu/vs/3436263067345159
机译:背景技术由于术前应用的细针穿刺活检方法有一定的局限性,因此经常需要区分甲状腺的恶性病变和良性病变。为了提高诊断准确性,已经研究了使用免疫细胞化学和免疫组织化学技术的标记物,主要是细胞角蛋白19(CK-19),半乳糖凝集素3(Gal-3)和Hector Battifora间皮1(HBME-1)。但是,目前的结果仍存在争议。本文的目的是确定CK-19,Gal-3和HBME-1标记物的诊断准确性以及它们在恶性和良性甲状腺病变鉴别中的关联。方法对MEDLINE和Cochrane图书馆上发表的文章进行系统评价。建立纳入和排除标准后,选择了66篇文章。采用诊断准确性的荟萃分析技术,计算灵敏度,特异性,总ROC曲线下面积和诊断比值比(dOR)的全局值。结果对于免疫组化技术,CK-19对甲状腺恶性病变的诊断呈阳性,总体敏感性为81%,特异性为73%。对于Gal-3,敏感性为82%,特异性为81%; HBME-1的敏感性为77%,特异性为83%。这三种标记的关联确定了85%的敏感性,97%的特异性和95.1的诊断比值比。免疫细胞化学分析也发现了相似的结果。结论这项荟萃分析表明,所研究的三种免疫标记物在甲状腺良性和恶性病变的术前和术后诊断中是准确的。然而,由于发现的结果仍然显示出假阴性和假阳性试验的持续性,因此必须继续寻找其他分子标记以提高诊断准确性。虚拟幻灯片http://www.diagnosticpathology.diagnomx.eu/vs/3436263067345159

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号